The impact of age on radium-223 distribution and an evaluation of molecular imaging surrogates
Radium-223 dichloride is the first alpha-particle emitting therapeutic agent approved by FDA and EMA for bone metastatic castration-resistant prostate cancer. We studied its age-dependent biodistribution in mice, and compared it with [99mTc]Tc-MDP and [18F]NaF aiming to identify a potential imaging surrogate to predict [223Ra]RaCl2 whole-body localization.
Source: Nuclear Medicine and Biology - Category: Nuclear Medicine Authors: Wen Jiang, David Ulmert, Brian W. Simons, Diane S. Abou, Daniel L.J. Thorek Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Molecular Biology | Nuclear Medicine | Prostate Cancer